This is a collection of grey literature and some archive material relating to drugs and drug policy, originally part of the library holdings at DrugScope (Wellcome)
Bibliography: Domestic Policy Issues
Cannabis-based products for medicinal use in humans: commission to the ACMD
The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use
National Drug Control Strategy (PDF)
A Report by the Office of National Drug Control Policy
Statement from FDA Commissioner Scott Gottlieb, M.D., on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths
With the number of overdose deaths involving prescription and illicit opioids more than doubling over the last seven years to nearly 48,000 in 2017, it’s critical that we continue to address this tragedy from all fronts. This includes new ways to increase availability of naloxone, a drug used to treat opioid overdose (FDA)
Review of the New Strategic Direction for Alcohol and Drugs – Phase 2
A report prepared for the Department of Health in Northern Ireland by the Institute of Public Health in Ireland (PDF)
State of the Nation 2018
The New Zealand Drug Foundation’s State of the Nation report is a snapshot of how New Zealand is dealing with alcohol and other drugs
Colorado publishes latest statistics on impact of cannabis legalisation
The state government instructed the state Department of Public Safety to report on key statistics of cannabis-related topics including crime, impaired driving, hospital visits, usage rates, effects on youth. A second biennial report was released in October 2018 (EMCDDA)
Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States
Data for 2017 indicate that there were more than 47,000 opioid-involved overdose deaths, and one in eight adults now reports having had a family member or close friend die from opioids. Increasing the availability and reducing the costs of approved medications for those with an opioid use disorder (OUD) is imperative; however, jurisdictions addressing OUDs and overdose may wish to consider additional interventions. Download (RAND)
He Ara Oranga : Report of the Government Inquiry into Mental Health and Addiction
The Inquiry Panel wanted to set a clear direction for the next five to ten years that Government, the mental health and addiction sectors and the whole community can pick up and make happen. Our purpose was to identify unmet needs and develop recommendations for a better mental health and addiction system for Aotearoa New Zealand
Guidance for drug and alcohol treatment providers and clients
Guidelines for drug and alcohol treatment providers on sharing client’s information with the National Drug and alcohol Treatment Monitoring System (NDTMS)
Review of the Psychoactive Substances Act 2016
This review sought to measure changes in outcomes before and after the implementation of the Act, to provide an indication of whether its aims are being achieved (Home Office)
Cannabis-based products for medicinal use: Guidance to clinicians
Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians
Police powers and procedures, England and Wales, year ending 31 March 2018 (PDF)
This release contains statistics on the use of various police powers in England and Wales up to the year ending 31 March 2018 (Home Office)
Pregabalin and gabapentin to be controlled as class C drugs
New controls over prescription drugs pregabalin and gabapentin following rising fatalities (Home Office)
Rescheduling of cannabis-based products for medicinal use:Written statement
Today, the Government is laying the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (“the 2018 Regulations”) in the House. These regulations reschedule cannabis-based products for medicinal use and will come into force on 1 November 2018 (Parliament, UK)
Alcohol, drugs and tobacco: commissioning support pack
Annual guidance on smoking, drinking and drug misuse for commissioners of tobacco control, drug and alcohol services for adults and young people (Public Health England)
Government’s response to the ACMD report on Medicinal cannabis
Eleven recommendations (Home Office)
5-Point Strategy To Combat the Opioid Crisis
HHS has a comprehensive strategy to empower local communities on the frontlines. The opioid epidemic is one of the Department’s top priorities. In 2017, HHS launched a 5-point Opioid Strategy
Further advice on scheduling of cannabis-derived medicinal products
Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products
Best Practices across the Continuum of Care for the Treatment of Opioid Use Disorder (PDF)
disorder in Canada should have access to comprehensive treatment options that meet all their needs. Best Practices across the Continuum of Care for the Treatment of Opioid Use Disorder presents services that should be available to individuals experiencing or at risk of experiencing harms from opioid use (CCSA)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »
